Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Judy Kafelghazal"'
Autor:
Andrew C. Birkeland, Megan L. Ludwig, Hui Jiang, Julia Eisenberg, Judy Kafelghazal, J. Chad Brenner, Matthew E. Spector, Jacqueline E. Mann, Thomas E. Carey, Aditi Kulkarni, Brittany M. Jewell
Publikováno v:
Head & neck, vol 41, iss 9
Head Neck
Head Neck
Background Laryngeal squamous cell carcinomas (LSCCs) have a high risk of recurrence and poor prognosis. Patient-derived cancer cell lines remain important preclinical models for advancement of new therapeutic strategies, and comprehensive characteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2437706dd247357e569f40fed28f510
https://escholarship.org/uc/item/57p9f9nc
https://escholarship.org/uc/item/57p9f9nc
Autor:
Chad Brenner, Aditi Kulkarni, Judy Kafelghazal, Julia Eisenberg, Alexey I. Nesvizhskii, Megan L. Ludwig, Rebecca C. Hoesli, Jacqueline E. Mann
Publikováno v:
Cancer Research. 78:3626-3626
The immune checkpoint inhibitor Pembrolizumab was recently approved for the treatment of metastatic and recurrent HNSCC, but only 18% of patients in the initial trial responded to therapy, and it remains difficult to predict patients likely to experi
Autor:
Alexey I. Nesvizhskii, Judy Kafelghazal, Jacqueline E. Mann, Megan L. Ludwig, Rebecca C. Hoesli, Aditi Kulkarni, J. Chad Brenner
Publikováno v:
Clinical Cancer Research. 23:28-28
Evidence of immunosuppression is frequently reported in head and neck squamous cell carcinoma (HNSCC). Thus, there has been growing interest in advancing therapies for HNSCC that relieving immunosuppression to permit anti-tumor immunity. The immune c